Toronto Dominion Bank
PTGX icon

Toronto Dominion Bank’s Protagonist Therapeutics PTGX Stock Holding History

Toronto Dominion Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,500
Closed -$1.88M – 2348
2025
Q4 		$1.88M Buy
+21,500
New +$1.76M ﹤0.01% 1139

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Toronto Dominion Bank's PTGX Position: Q1 2026 in Review

Toronto Dominion Bank opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 349 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #1805 among its holdings. This is a return to the name: Toronto Dominion Bank previously reported a position in PTGX as recently as Q3 2025.

Toronto Dominion Bank first reported a position in PTGX in Q4 2024 and has held it in 5 quarters since. The position peaked at $29.6M in Q3 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Toronto Dominion Bank held 349 shares of Protagonist Therapeutics worth $36.8K as of Q1 2026.
  • Protagonist Therapeutics was a new Toronto Dominion Bank position in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #1805 holding.
  • Toronto Dominion Bank first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Toronto Dominion Bank's Protagonist Therapeutics position peaked at $29.6M in Q3 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.